On October 12, 2021, NewMed Medical was ranked in 2021 TOP 10 Chinese medical device innovative companies at the Sixth China Great Health Industry Upgrading Summit. The summit was hosted by the General Practice and Health Management Committee of China Health Information and Healthcare Big Data Society under the guidance of Sichuan Provincial Health and Health Commission and China Health Information and Health Care Big Data Society, and supported by West China Hospital of Sichuan University.

 
The list of TOP 10 Chinese medical device innovation companies 2021 focuses on the most innovative and dynamic health enterprises in China, and 10 medical device innovation enterprises were finally elected with comprehensive consideration of hard indicators such as financing rounds and operations, as well as soft factors such as the prospect of the track in which the enterprise is, enterprise innovation, product differentiation degree, and the quality of products or services.

NewMed Medical is a high-end medical device company dedicated to the R&D and industrialization of artificial heart valves and catheter implantation systems, with complete capacity for independent R&D, testing and production. The company's product line covers mitral valve, aortic valve, pulmonary valve and tricuspid valve. As one of the players with the broadest product line for valve intervention in China, the company is strategically focusing on mitral valve replacement and mitral valve repair, aortic valve replacement, tricuspid valve replacement and repair, pulmonary valve replacement, and auxiliary devices such as high-pressure balloons and Suture-mediated closure system for comprehensive product planning to provide the leading comprehensive innovative solutions for valve interventions in China.

NewMed Medical currently has three products approved into the Special Review Procedures for Innovative Medical Devices (“green channel”) according to the Special Review Procedures for Innovative Medical Devices promulgated by NMPA, and they have entered the clinical registration stage.

Insisting on innovation as the first driving force and adhering to the tenet of “Innovations Improve Life”, the company has independently developed and improved its native advanced R&D technology platform, covering comprehensive technology platforms required for heart valve R&D, including medical metal material platform, medical polymer material platform, biological tissue platform and large balloon catheter platform, laying a solid foundation for the steady progress of the existing R&D projects and the continuous expansion of the product pipeline. Leveraging its experience in product development in the field of valve intervention, the company continues to identify unmet clinical needs and clinical feedback in the market, study the technical pathways that can be widely applied to the clinical setting, and promote product finalization and clinical validation, to realize a broad product and business development in the entire structural heart disease field.